Axonal sensorimotor polyneuropathy is a condition in which the long, cable-like extensions of nerve cells, called axons, degenerate in a pattern that affects both sensation and movement, typically starting in the feet and creeping upward over time. It is the most common form of polyneuropathy, accounting for the vast majority of cases seen in clinical practice, and diabetes is its single leading cause. The term itself is a compressed description: “axonal” identifies the part of the nerve that is damaged, “sensorimotor” tells you both feeling and muscle control are involved, and “polyneuropathy” means many nerves are affected at once. Despite how common it is, many people first encounter the diagnosis on a nerve-conduction study report and have no idea what it means or what to expect.
Axonal Versus Demyelinating Damage
Every peripheral nerve is built from two main components: the axon itself, which carries electrical signals, and a fatty insulating sheath called myelin that wraps around it and speeds up those signals. When the myelin is the primary target, the result is a demyelinating neuropathy, which shows up on nerve-conduction studies as dramatically slowed signal speeds, signal dispersion, and conduction block. When the axon is the primary target, the nerve signals may travel at nearly normal speeds but are weaker because fewer axons are functioning. In axonal neuropathy, nerve-conduction studies typically show small signal amplitudes rather than marked slowing.
This distinction matters because the two categories often point to different causes and carry different treatment implications. Demyelinating polyneuropathies are more likely to involve inflammatory or immune-mediated processes that can sometimes be treated aggressively with immunotherapy. Axonal polyneuropathies span a wider landscape of causes, from metabolic problems to toxins to genetics, and treatment usually revolves around addressing the underlying trigger and managing symptoms. In practice, the boundary is not always clean. A study comparing nerve recordings from distal and proximal muscles found that patients with axonal neuropathies showed conduction slowing preferentially in recordings from distal muscles, while proximal recordings remained relatively normal, helping clinicians separate the two when results overlap.1PubMed. Differentiation between axonal and demyelinating neuropathies: identical segments recorded from proximal and distal muscles A separate analysis cautioned that amplitude reduction alone should be interpreted carefully and that other conduction parameters are more reliable for pinpointing whether the underlying damage is axonal or demyelinating.2PubMed. Correlations of nerve conduction measures in axonal and demyelinating polyneuropathies
Why Symptoms Start in the Feet
If you picture a nerve as a supply line running from the spinal cord all the way to the tip of a toe, the far end of that line is the most vulnerable. The classical explanation for axonal polyneuropathy’s “stocking-glove” pattern, where symptoms begin in the toes, climb to the ankles, and eventually reach the fingertips, is a process called dying-back degeneration. The traditional view held that the distal end of the axon degenerates first because it sits farthest from the nerve cell body and receives the least nutritional support, like the last field on an irrigation canal. Newer research has complicated that picture by identifying problems with retrograde axonal transport in a variety of nervous system disorders, suggesting the process may not be as straightforwardly distance-dependent as once thought.3JAMA Neurology. Neuroprotection in the Peripheral Nervous System: Rationale for More Effective Therapies Still, the clinical result is the same: the longest nerves fail first, so symptoms almost always appear in the feet before the hands.
This length-dependent pattern is so characteristic that its absence is actually a diagnostic red flag. When numbness or weakness shows up in the hands before the feet, or appears on one side of the body more than the other, clinicians start considering alternative diagnoses such as a focal nerve lesion, a radiculopathy from spinal nerve root compression, or a non-length-dependent process like a ganglionopathy.
Common Causes
The list of things that can damage axons is long, but a handful of causes dominate the clinical landscape.
Diabetes and Metabolic Disease
Diabetes is responsible for more than half of peripheral neuropathy cases in Western populations.4JAMA. Peripheral Neuropathy: A Review Persistently high blood sugar, disordered lipid metabolism, and abnormal insulin signaling all contribute to the disruption of normal structure and function throughout the peripheral nervous system, affecting both myelinated and unmyelinated axons, blood vessels supplying the nerves, and supporting glial cells.5PubMed Central. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment Diabetic neuropathy often features sensory symptoms such as pain, tingling, or numbness alongside mild weakness and autonomic symptoms like blood pressure drops when standing.4JAMA. Peripheral Neuropathy: A Review Prediabetes and metabolic syndrome can also cause neuropathy, so the damage sometimes begins before a person is formally diagnosed with diabetes.
Alcohol and Nutritional Deficiency
Chronic heavy drinking is another major contributor. The mechanism involves a double hit: alcohol itself is directly toxic to nerves, and people who drink heavily are frequently deficient in B vitamins, especially thiamine (vitamin B1). Both the direct toxicity and the nutritional deficiency appear to play a role in the nerve damage and pain that develop.6PubMed Central. Alcoholic neuropathy: possible mechanisms and future treatment possibilities Severe thiamine deficiency alone, even without alcohol, can cause axonal neuropathy; this is occasionally seen in people with bariatric surgery, prolonged vomiting, or severely restricted diets.
Chemotherapy and Other Drug Toxicity
Several classes of chemotherapy drugs are notorious for causing axonal damage, a problem broadly known as chemotherapy-induced peripheral neurotoxicity. Taxanes, vinca alkaloids, epothilones, and proteasome inhibitors all interfere with the microtubule structures inside axons. Microtubules serve as the railroad tracks along which nutrients and cellular cargo are transported up and down the nerve fiber. When drugs hyperstabilize, destabilize, or otherwise disrupt microtubule dynamics, both forward and backward transport along the axon can stall, eventually leading to degeneration.7PubMed Central. Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence The resulting neuropathy can persist long after chemotherapy ends, which frustrates many cancer survivors.
Inherited Neuropathies
Genetic causes are less common but worth knowing about, particularly Charcot-Marie-Tooth disease type 2 (CMT2), the primary inherited form of axonal neuropathy.8PubMed Central. Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities CMT2 can result from mutations in many different genes. One well-studied example is MFN2, a gene involved in mitochondrial function. Mutations in MFN2 can cause neuropathies of varying severity with either dominant or recessive inheritance, which means a family may show wildly different patterns of disease even when carrying the same mutation.9JAMA Neurology. Genotype-Phenotype Correlations in Charcot-Marie-Tooth Disease Type 2 Caused by Mitofusin 2 Mutations Genetic testing has become increasingly accessible and is now recommended for anyone with unexplained axonal neuropathy, especially if symptoms began before middle age or there is a family history.
Autoimmune and Systemic Disease
Conditions that deposit abnormal proteins in nerves, such as amyloidosis, can produce a sensorimotor polyneuropathy characterized by neuropathic pain, numbness, and progressive weakness.10PubMed Central. Amyloid neuropathies Vasculitis, sarcoidosis, and certain paraprotein disorders can also target axons, sometimes producing asymmetric or multifocal patterns rather than the typical stocking-glove distribution.
When No Cause Can Be Found
After an extensive workup, a large proportion of axonal polyneuropathy cases have no identifiable cause. This diagnosis of exclusion is called chronic idiopathic axonal polyneuropathy, or CIAP, and it accounts for roughly 10% to 25% of people referred for evaluation of polyneuropathy.11PubMed Central. Drug therapy for chronic idiopathic axonal polyneuropathy A large retrospective study of 785 elderly patients with neuropathy found that about 35% had no identifiable cause, and over 93% of all cases in that population were axonal rather than demyelinating.12European Geriatric Medicine. Causes of neuropathy in the elderly: A retrospective study with 785 patients
CIAP predominantly affects older adults. The typical picture is a slowly progressive sensory or sensorimotor neuropathy that causes mild to sometimes moderate disability and reduces quality of life, though it rarely leads to severe disability.13Brain. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy For many people the frustration of an “idiopathic” label is worse than the symptoms themselves. It is worth noting that the label may evolve: diabetes, prediabetes, and subtle nutritional deficiencies are occasionally uncovered years later.
What It Feels Like
Because both sensory and motor fibers are involved, axonal sensorimotor polyneuropathy produces a distinctive combination of symptoms.
On the sensory side, numbness, tingling, burning, and pain in the feet and lower legs are usually the earliest complaints. The numbness may be subtle at first, noticed only as a feeling that the floor seems different underfoot. Over time it becomes harder to detect temperature, sharp objects, or the position of the toes. Some people develop hypersensitivity where even bedsheets touching the feet become painful, a phenomenon called allodynia. Whether pain is prominent varies widely between individuals and even between causes: chemotherapy-induced neuropathy can be intensely painful, while some idiopathic cases cause numbness without significant pain.
On the motor side, weakness tends to arrive later and starts distally, affecting muscles in the feet and ankles. Research in diabetic neuropathy found that muscle weakness appears only in patients who already have evidence of neuropathy, and the severity of weakness tracks closely with the overall severity of nerve damage.14PubMed. Motor dysfunction in diabetes Imaging studies show that the weakness is accompanied by actual muscle wasting in the feet and lower legs. The practical consequences are real: difficulty lifting the front of the foot (foot drop), unstable gait, and more frequent falls.14PubMed. Motor dysfunction in diabetes In advanced cases, hand grip and fine motor coordination deteriorate as the process reaches the upper limbs.
How It Is Diagnosed
Diagnosis usually begins with a clinical examination focused on reflexes, sensation, and strength, especially in the feet and hands. If the pattern looks like a length-dependent polyneuropathy, the next step is typically electrodiagnostic testing, which includes nerve-conduction studies and electromyography. These tests measure how fast electrical signals travel along nerves and how well muscles respond. In axonal sensorimotor polyneuropathy, the hallmarks are reduced amplitudes of compound muscle action potentials and sensory nerve action potentials, with conduction velocities that are only marginally slowed.15PubMed Central. Diagnostic approach to peripheral neuropathy
Standard nerve-conduction studies capture the behavior of large myelinated fibers but miss damage to small unmyelinated fibers, which carry pain and temperature signals. When symptoms are prominent but nerve-conduction results look normal, a skin biopsy can help. A small punch biopsy, usually taken from the lower leg, allows pathologists to count the density of tiny nerve fibers in the skin. European guidelines rate this technique as highly sensitive for diagnosing small-fiber neuropathy, more so than sensory nerve conduction studies or sural nerve biopsy.16PubMed. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy An American evidence-based review similarly concluded that skin biopsy is a validated tool for diagnosing polyneuropathy, particularly small-fiber types.17PubMed. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review)
Blood work plays a large role in finding the cause. A standard initial workup typically includes fasting glucose and hemoglobin A1c, a complete blood count, vitamin B12, thyroid function, kidney and liver tests, and serum protein electrophoresis. Depending on the clinical picture, additional testing may include genetic panels, inflammatory markers, or testing for specific autoantibodies. When nerve-conduction patterns look like lumbosacral radiculopathy rather than polyneuropathy, a study comparing the two found that certain patterns of motor-conduction abnormalities can help tell them apart, correctly classifying disease in about three-quarters of subjects.18Muscle & Nerve. Comparison of motor conduction abnormalities in lumbosacral radiculopathy and axonal polyneuropathy
Treatment and Management
The most effective treatment for axonal sensorimotor polyneuropathy is addressing whatever is causing it. For diabetic neuropathy, improved blood sugar control slows progression and may partially reverse early damage. For alcohol-related neuropathy, stopping drinking and replenishing thiamine and other B vitamins can halt further deterioration. For chemotherapy-induced neuropathy, dose adjustments or switching agents may be necessary, though the damage sometimes persists after treatment ends.
When the cause is idiopathic or cannot be fully corrected, management focuses on symptoms. Pain is often the most burdensome complaint. A broad evidence review found that four classes of oral medication reduce neuropathic pain: tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs), sodium-channel blockers, and gabapentinoids.19CMAJ. Diagnosis and management of patients with polyneuropathy The effect sizes were similar across all four classes, so any of them can be a reasonable first choice. What matters practically is setting realistic expectations: the goal of medication is to reduce pain, not eliminate it.19CMAJ. Diagnosis and management of patients with polyneuropathy Many people try more than one medication before finding something tolerable and effective. For CIAP specifically, a Cochrane review found insufficient evidence that any drug therapy prevents disease progression, meaning current treatment remains symptomatic rather than disease-modifying.11PubMed Central. Drug therapy for chronic idiopathic axonal polyneuropathy
Beyond medication, physical therapy and targeted exercise are valuable for maintaining strength, improving balance, and reducing fall risk. Ankle-foot orthoses can compensate for foot drop. Occupational therapy can address hand function when the upper limbs are involved. Foot care is particularly important for anyone with numbness in the feet, because minor injuries, blisters, and infections can go unnoticed and spiral into serious problems.
What Happens to Damaged Axons
Unlike many cells in the central nervous system, peripheral axons do have some capacity to regenerate. When an axon is damaged, regrowth begins at the proximal stump and advances at a rate of roughly one millimeter per day.20Journal of Hand Surgery Global Online. Original Research Advancing Peripheral Nerve Regeneration (Nerve SPACE 2025) That translates to about an inch per month, which explains why recovery from nerve injuries is measured in months to years, not weeks. For a polyneuropathy where the axonal damage is ongoing rather than a one-time injury, regeneration is constantly competing against continued degeneration. If the underlying cause is controlled, regeneration can sometimes gain the upper hand, which is why some people experience partial improvement in sensation and strength after their diabetes or nutritional deficiency is addressed.
However, there are limits. When nerve cell bodies themselves are destroyed rather than just axons, regeneration cannot occur. Chronic axonal loss also leads to permanent muscle atrophy if motor nerves are never re-established. This is why early diagnosis and cause-directed treatment matter: the longer axonal damage continues unopposed, the less recovery is possible.
Neurofilament Light Chain as an Emerging Biomarker
One frustration with axonal polyneuropathy is that tracking how quickly axons are degenerating has historically required repeated nerve-conduction studies, which are uncomfortable and only capture large-fiber health. A blood test measuring serum neurofilament light chain (NfL), a structural protein released when axons break down, has been generating considerable interest. In a study of people with diabetes, higher serum NfL levels were associated with the presence of sensorimotor polyneuropathy and with slower nerve conduction velocities, lower sensory nerve signal amplitudes, and higher sensory thresholds.21PubMed Central. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy A further study confirmed that higher NfL correlated with loss of nerve fiber density in skin biopsies and with more pronounced nerve-fiber dysfunction, though it did not correlate with pain severity or clinical neuropathy scales.22PubMed. Serum Neurofilament Light Chain and Structural and Functional Nerve Fiber Loss in Painful and Painless Diabetic Polyneuropathy
NfL is not specific to any single disease. It rises in multiple sclerosis, traumatic brain injury, and neurodegenerative diseases as well. But for polyneuropathy, its promise lies in monitoring: a simple blood draw could potentially tell clinicians whether a treatment is slowing down axonal damage or whether things are getting worse, without requiring another nerve-conduction study. Research in chronic inflammatory demyelinating polyneuropathy found that elevated NfL early in the disease course indicated severe axonal damage requiring aggressive treatment.23PubMed Central. Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment Outcome The test is not yet standard in routine neuropathy care, but it is increasingly available in clinical laboratories and may become a regular part of the monitoring toolkit in the coming years.